Study of Desorbtion and Exemption of Terpeno-indole Alkaloids of Vinkristin and Vinblastin from Erythrocitary Cell Carriers
https://doi.org/10.33380/2305-2066-2019-8-2-16-21
Abstract
Introduction. Employees of the Department of Pharmaceutical Chemistry and Pharmaceutical Technology have obtained modified forms of terpino-indole alkaloids (ТIA) and vinbristine (VCR) and vinblastine (VBL) known in the treatment of cancer diseases by incorporating them into the erythrocyte carriers (EN) by the modified method of hypoosmotic lysis in the modified (aprotic solvent dimethyl sulfoxide (DMSO) and polyethylene glycol (PEG 4000) and unmodified media.
Aim. The aim of the work was to study the desorption and release of terpene-indole vincristine and vinblastine alkaloids from previously obtained cellular erythrocyte carriers.
Materials and methods. In the experiment performed, the release characteristics of encapsulated preparations from erythrocytes were determined. TIA preparations were released from erythrocyte form in 6 hours: VCR – 54.5305%, VCR : PEG-4000 (1:5) – 53.3305%, VCR : PEG-4000 (1:10) – 40.1283%, VCR : PEG-4000 (1:20) – 39.9869%, VCR : DMSO (2 mg/ml) – 54.2354%, VBL – 68.0656%; VBL : PEG-4000 (1:10) – 63.8941%; VBL : PEG-4000 (1:20) – 60.7455%; VBL : PEG-400 (1:20) – 60.3529%; VBL : DMSO (2 mg/ml) – 64.5006%. The rate of release from an erythrocyte form encapsulated in a medium modified with DMSO is significantly higher than that encapsulated in an unmodified medium. The average rate of TIA release from erythrocyte forms encapsulated in PEG medium is approximately the same.
Results and discussion. The results show that the release of hemoglobin from TIA encapsulated erythrocytes compared with non-encapsulated EN is small. The results show that, on average, 8.242 ± 0.3135% of hemoglobin is released from TIA encapsulated with EN, compared to control erythrocytes – 7.53% after 6 h of incubation at 37 °C. The release of hemoglobin from the TIA of encapsulated erythrocytes in modified media is less than that encapsulated in unmodified medium.
Conclusion. Based on these results, it can be suggested that PEG can bind to the erythrocyte membrane and stabilize it.
About the Authors
O. V. Trineeva
Voronezh State University
Russian Federation
Russian Federation
A. D. Khalahakun
Voronezh State University
Russian Federation
Russian Federation
References
1. Trineeva O. V. et al. Morphological and physicochemical properties of erythrocyte carriers encapsulated with terpene-indole alkaloids. Drug development & registration. 2018; 1(22): 40–44 (In Russ.).
2. Zaborovsky A. V., Gurevich K. G. Modeling of the directed transport of medicinal substances. Part I. Single management. Siberian Oncology Journal. 2017; 1(16): 59–65 (In Russ.).
3. Zaborovsky A. V., Gurevich K. G. Modeling of the directed transport of medicinal substances. Part II. Repeated introduction. Siberian Oncology Journal. 2017; 2(16): 36–41 (In Russ.).
4. Kseiko D. A., Gening T. P. Efficiency of using autologous blood cells for targeted delivery of ascorbic acid to the liver in order to optimize the colloid osmotic pressure of blood after blood loss. Ulyanovsk Biomedical Journal. 2014; 2: 67–72 (In Russ.).
5. Levin G. Ya., Sosnina L. N. The use of ultraviolet irradiation of erythrocytes to increase their ability to deposit drugs. Medical Almonas. 2013; 3(27): 67–69 (In Russ.).
6. Levin G. Ya., Sosnina L.N. Investigation of the rheological properties of erythrocytes modified for the directed transport of drugs. Basic research. 2013; 2(1): 105–109 (In Russ.).
7. Ivonin A.G. and others. Directed transport of drugs: current state of the issue and prospects. Proceedings of the Komi Scientific Center UB RAS. 2012; 1(9) (In Russ.).
8. Banskota S. et al. Cell-Based Biohybrid Drug Delivery Systems: The Best of the Synthetic and Natural Worlds. 2017; 17(1).
9. Bourgeaux V. et al. Drug-loaded erythrocytes: on the road toward marketing approval. Drug design, development and therapy. 2016; 10: 665–676.
10. Coker S. A. et al. A Study of the Pharmacokinetic Properties and the In Vivo Kinetics of Erythrocytes Loaded With Dexamethasone Sodium Phosphate in Healthy Volunteers. Transfusion Medicine Reviews. 2017. DOI: https://doi.org/10.1016/j.tmrv.2017.09.001
11. Deloach J. et al. Effect of glutaraldehyde treatment on enzyme-loaded erythrocytes. Biochimica et Biophysica Acta (BBA) – General Subjects. 1977; 496(2): 507–515.
12. Sun Y. et al. Advances of blood cell-based drug delivery systems. European Journal of Pharmaceutical Sciences. 2017; 96: 115–128.
13. Zocchi E. et al. Encapsulation of doxorubicin in liver-targeted erythrocytes increases the therapeutic index of the drug in a murine metastatic model. Proceedings of the National Academy of Sciences of the United States of America. 1989; 86(6): 2040–2044.
14. Rossi L. et al. Engineering erythrocytes for the modulation of drugs’ and contrasting agents’ pharmacokinetics and biodistribution. Advanced Drug Delivery Reviews. 2016; 106: 73–87.
15. Villa C. H. et al. Erythrocytes as Carriers for Drug Delivery in Blood Transfusion and Beyond. Transfusion Medicine Reviews. 2017; 31(1): 26–35.
16. Kravtzoff R. et al. Erythrocytes as carriers for L-asparaginase. Methodological and mouse in-vivo studies. The Journal of pharmacy and pharmacology. 1990; 42(7): 473–476.
17. Field W. N. et al. A comparison of the treatment of thyroidectomized rats with free thyroxine and thyroxine encapsulated in erythrocytes. International Journal of Pharmaceutics. 1989; 51(2): 175–178.
18. Harisa G.E. et al. Characterization of human erythrocytes as potential carrier for pravastatin: An in vitro study. International Journal of Medical Sciences. 2011; 8(3): 222–230.
19. Hu C. M. J. et al. Erythrocyte-inspired delivery systems. Advanced Healthcare Materials. 2012; 1(5): 537–547.
20. Favretto M.E. [et al.] Human erythrocytes as drug carriers: Loading efficiency and side effects of hypotonic dialysis, chlorpromazine treatment and fusion with liposomes. Journal of Controlled Release. 2013; 170(3): 343–351.
21. Ihler G. M. Tsang H. C. Hypotonic hemolysis methods for entrapment of agents in resealed erythrocytes. Methods in enzymology. 1987; 149: 221–229.
22. Magnani M. et al. Erythrocyte Engineering for Drug Delivery and Targeting. Texas. Eurekah.com. 2002; 151.
23. Magnani M., DeLoach J. R. The Use of Resealed Erythrocytes as Carriers and Bioreactors: Advances in Experimental Medicine and Biology. Boston. Springer US. 1992; 341.
24. Skorokhod O. A. et al. Pharmacokinetics of erythrocyte-bound daunorubicin in patients with acute leukemia. Medical science monitor: international medical journal of experimental and clinical research. 2004; 10(4): 155–164.
25. Bhimavarapu R. et al. Resealed erythrocytes as a targeted drug delivery system – an overview. PHARMANEST An International Journal of Advances in Pharmaceutical Sciences. 2012; 3(1): 47–64.
26. Wu Y. W. et al. Smart blood cell and microvesicle-based Trojan horse drug delivery: Merging expertise in blood transfusion and biomedical engineering in the field of nanomedicine. Transfusion and Apheresis Science. 2016; 54(2): 309–318.
27. Sprandel U. et al. Erythrocytes as Drug Carriers in Medicine. Boston, MA: Springer US. 1997; 149.
28. Sprandel U., Zöllner N. Osmotic fragility of drug carrier erythrocytes. Research in Experimental Medicine. 1985; 185(1): 77–85.
29. Thorpe S. R. et al. Enzyme Therapy. V. In Vivo Fate of Erythrocyteentrapped β-Glucuronidase in β-Glucuronidase-deficient mice. Pediatric Research. 1975; 9(12): 918–923.
30. Tuhin F. T. et al. Essentials of Single-Cell Analysis: Series in BioEngineering. Berlin, Heidelberg: Springer Berlin Heidelberg. 2016; 325–346.
31. Updike S. et al. Asparaginase entrapped in red blood cells: action and survival. Science. 1976; 193(4254): 681–683.
32. Halakhakun A.D. Production and standardization of erythrocyte carriers encapsulated with terpene-indole alkaloid antineoplastic drugs: Sc.D. Moscow. 2018; 26.
Review
For citations:
Trineeva O.V., Khalahakun A.D. Study of Desorbtion and Exemption of Terpeno-indole Alkaloids of Vinkristin and Vinblastin from Erythrocitary Cell Carriers. Drug development & registration. 2019;8(2):16-21. (In Russ.) https://doi.org/10.33380/2305-2066-2019-8-2-16-21
Views:
1295
Email this article 